Search

Displaying results 7201 - 7210 of 10000 in total
  1. Drug

    Opnurasib

    go.drugbank.com/drugs/DB21583
    Investigational

    Opnurasib is under investigation in clinical trial NCT05132075 (Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer … Opnurasib is a small molecule drug. The usage of the INN stem '-rasib' in the name indicates that Opnurasib is a Ras protein inhibitor.

  2. Drug

    KITE-585

    go.drugbank.com/drugs/DB17409
    Investigational

    KITE-585 is an autologous, fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. It is being investigated in the treatment of multiple myeloma.

  3. Drug

    Metribolone

    go.drugbank.com/drugs/DB02998
    Experimental

    It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.

  4. Drug

    Carlumab

    go.drugbank.com/drugs/DB12718
    ApprovedWithdrawn

    Carlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.

  5. Drug

    Anfibatide

    go.drugbank.com/drugs/DB15094
    Investigational

    Anfibatide is under investigation in clinical trial NCT01585259 (Anfibatide Phase Ib-IIa Clinical Trial).

  6. Drug

    Ochromycinone

    go.drugbank.com/drugs/DB15644
    Investigational

    Ochromycinone is under investigation in clinical trial NCT01047943 (STA-21 Topical Efficacy on Psoriasis).

  7. Drug

    CoviGlobulin

    go.drugbank.com/drugs/DB15747
    Experimental

    The antibodies themselves are produced in response to an immunogen and derived from antibody-producing plasma cells that were once B-cell clones. … Different antibodies have different mechanisms of action depending on their target.

  8. Drug

    Talopram

    go.drugbank.com/drugs/DB09190
    Experimental

    Talopram is a selective norepinephrine reuptake inhibitor (SNRI) that is structurally similar to citalopram and melitracen. It was researched in the 1960s and 1970s but never marketed.

  9. Drug

    MRK-003

    go.drugbank.com/drugs/DB17015
    Experimental

    MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682]

  10. Drug

    CP-778875

    go.drugbank.com/drugs/DB19211
    Investigational

    CP-778875 is under investigation in clinical trial NCT00326326 (Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.).